Left atrial diameter is a simple indicator of a deficiency in atrial natriuretic peptide secretion in patients with mitral stenosis: Efficacy of postoperative supplementation with synthetic human α-atrial natriuretic peptide

Journal of Cardiovascular Pharmacology

Volumn 44, Issue 6, 2004, Pages 709-717

  Hayashi, Yoshitaka ^a   Ohtani, Masakatsu ^a   Sawa, Yoshiki ^b   Hiraishi, Taizo ^a   Kobayashi, Yasuhiko ^a   Matsuda, Hikaru ^b  

^a MINAMI OSAKA GENERAL HOSPITAL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Atrial natriuretic peptide; Chronic heart failure; Left atrial diameter; Mitral valve diseases; Renin angiotensin system

Indexed keywords

ALDOSTERONE; ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR ALPHA; RENIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT ATRIUM; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REPLACEMENT; MITRAL VALVE STENOSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; SUPPLEMENTATION; TIME SERIES ANALYSIS;

AGED; ATRIAL NATRIURETIC FACTOR; FEMALE; HEART; HEART ATRIA; HEART VALVE PROSTHESIS IMPLANTATION; HEMODYNAMIC PROCESSES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; MITRAL VALVE STENOSIS; POSTOPERATIVE CARE;

EID: 9744232089     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200412000-00014     Document Type: Article

References (37)

1. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism to disease progression in heart failure. J Am Coll Cardiol. 1992;20:248-254.
2. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96:526-534.
3. Saito Y, Nakao K, Arai H, et al. Augmented expression of atrial natriuretic polypeptide gene in ventricle of human failing heart. J Clin Invest. 1989;83:298-305.
4. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195-203.
5. Iwai N, Shimoike H, Kinoshita M. Cardiac renin angiotensin system in the hypertrophied heart. Circulation. 1995;92:2690-2696.
6. Hokimoto S, Yasue H, Fujimoto K, et al. Expression of angiotensin-converting enzyme in remaining viable myocytes of human ventricles after myocardial infarction. Circulation. 1996;94:1513-1518.
7. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation. 2001;103:72-77.
8. Cody RJ, Atlas SA, Laragh JH, et al. Atrial natriuretic factor in normal subjects and heart failure patients: plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion. J Clin Invest. 1986;78:1362-1374.
9. Bates ER, Shenker Y, Grekin RJ. The relationship between plasma levels of immunoreactive atrial natriuretic hormone and hemodynamic function in man. Circulation. 1986;73:1155-1161.
10. Saito Y, Nakao K, Nishimura K, et al. Clinical application of atrial natriuretic peptide in patients with congestive heart failure: beneficial effects on left ventricular function. Circulation. 1987;76:115-124.
11. Yoshimura M, Yasue H, Okumura K, et al. Different secretion pattern of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation. 1993;87:464-469.
12. Tsutamoto T, Kanamori T, Wada A, et al. Uncoupling of atrial natriuretic peptide extraction and cyclic guanosine monophosphate production in the pulmonary circulation in patients with severe heart failure. J Am Coll Cardiol. 1992;20:541-546.
13. Gottlieb SS, Kukin ML, Ahern D, et al. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol. 1989;13:1534-1539.
14. Dickstein K, Aarsland T, Hall C. Plasma N-terminal atrial natriuretic factor: a predictor of survival in patients with congestive heart failure. J Card Fail. 1997;3:83-89.
15. Nishimura K, Matsuda K, Nonno S, et al. Beneficial effect of synthetic human atrial natriuretic polypeptide on renal function in a patient with giant atria. J Thorac Cardiovasc Surg. 1997;113:793-795.
16. Maeda K, Tsutamoto T, Wada A, et al. Low dose synthetic human atrial natriuretic peptide infusion in a patient with mitral stenosis and severe pulmonary hypertension. Jpn Circ J. 1999;63:816-818.
17. Hayashi Y, Ohtani M, Hiraishi T, et al. Postoperative synthetic human atrial natriuretic peptide infusion and oral spironolactone administration for a patient with giant atria and low plasma level of atrial natriuretic peptide. J Thorac Cardiovasc Surg. 2002;124:206-209.
18. Hiramatsu T, Imai Y, Takanashi Y, et al. Hemodynamic effects of human atrial natriuretic peptide after modified Fontan procedure. Ann Thorac Surg. 1998;65:761-764.
19. Hama N, Nakao K, Mukoyama M, et al. Fundamental and clinical evaluation of 'Shionoria ANP', human atrial natriuretic peptide IRMA kit. Clin Rep. 1991;25:455-462.
20. Yasue H, Yoshimura M, Jougasaki M, et al. Plasma levels of brain natriuretic peptide in normal subjects and patients with chronic heart failure: measurement by immunoradiometric assay (IRMA). Horm Clin. 1993;41:397-403.
21. Yamaguchi H, Yoshida J, Yamamoto K, et al. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol. 2004;43:55-60.
22. Hayashi Y. Ohtani M, Hiraishi T, et al. Synthetic human α-atrial natriuretic peptide infusion in management after open heart operations. ASAIO J. 2003;49:320-324.
23. Hayashi Y, Ohtani M, Sawa Y, et al. Minimally-diluted blood cardioplegia supplemented with potassium and magnesium for combination of "initial, continuous and intermittent bolus" administration. Circ J. 2004;68:467-472.
24. Kosakai Y. How I perform the Maze procedure? Operative Techniques in Thoracic and Cardiovascular Surgery. 2000;5:23-45.
25. Davidson NC, Naas AA, Hanson JK, et al. Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol. 1996;77:828-831.
26. Downing SW, Edmunds LH Jr. Release of vasoactive substances during cardiopulmonary bypass. Ann Thorac Surg. 1992;54:1236-1243.
27. Sezai A, Shiono M, Orime Y, et al. Low-dose continuous infusion of human atrial natriuretic peptide during and after cardiac surgery. Ann Thorac Surg. 2000;69:732-738.
28. Connelly TP, Francis GS, Williams KJ, et al. Interaction of intravenous atrial natriuretic factor with furosemide in patients with heart failure. Am Heart J. 1994;127:392-399.
29. Cataliotti A, Boerrigter G, Costello-Boerrigter LC, et al. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation. 2004;109:1680-1685.
30. Maack T, Suzuki M, Almeida FA, et al. Physiological role of silent receptors of atrial natriuretic factor. Science. 1987;238:675-678.
31. Erdos EG, Skidgel RA. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J. 1989;3:145-151.
32. Charles CJ, Espiner EA, Nicholls MG, et al. Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am J Physiol. 1996;(2 pt. 2)271:R373-R380.
33. Cao L, Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension. 1995;25:227-234.
34. Fujisaki H, Ito H, Hirata Y, et al. Natriuretic peptides inhibit angiotensin II induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest. 1995;96:1059-1065.
35. Calderone A, Thaik CM, Takahashi N, et al. Nitric oxide, atrial natriuretic peptide and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest. 1998;101:812-818.
36. Tsukagoshi H, Shimizu Y, Kawata T, et al. Atrial natriuretic peptide inhibits tumor necrosis factor-alpha production by interferon-gamma-activated macrophages via suppression of p38 mitogen-activated protein kinase and nuclear factor-kappa B activation. Regul Pept. 2001;99:21-29.
37. McDowell G, Coutie W, Shaw C, et al. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. Br J Clin Pharmacol. 1997;43:329-332.